Immunocore Competitors

Abcam (NASDAQ:ABCM) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Abcam and Immunocore's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Abcam and Immunocore, as reported by MarketBeat.

Abcam currently has a consensus price target of $22.00, indicating a potential upside of 3.48%. Immunocore has a consensus price target of $54.3333, indicating a potential upside of 34.79%. Given Immunocore's stronger consensus rating and higher probable upside, analysts plainly believe Immunocore is more favorable than Abcam.

Valuation & Earnings

This table compares Abcam and Immunocore's gross revenue, earnings per share (EPS) and valuation.

Summary

Immunocore beats Abcam on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Valuation and Earnings

This table compares Immunocore and Recursion Pharmaceuticals' revenue, earnings per share and valuation.

Profitability

This table compares Immunocore and Recursion Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for Immunocore and Recursion Pharmaceuticals, as provided by MarketBeat.com.

Immunocore currently has a consensus target price of $54.3333, suggesting a potential upside of 34.79%. Given Immunocore's higher possible upside, equities analysts plainly believe Immunocore is more favorable than Recursion Pharmaceuticals.

Summary

Immunocore beats Recursion Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sana Biotechnology and Immunocore, as reported by MarketBeat.

Sana Biotechnology currently has a consensus price target of $40.00, suggesting a potential upside of 120.14%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 34.79%. Given Sana Biotechnology's higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Immunocore.

Valuation & Earnings

This table compares Sana Biotechnology and Immunocore's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Sana Biotechnology and Immunocore's net margins, return on equity and return on assets.

Immunocore (NASDAQ:IMCR) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and Seer, as reported by MarketBeat.com.

Immunocore currently has a consensus price target of $54.3333, suggesting a potential upside of 34.79%. Seer has a consensus price target of $68.00, suggesting a potential upside of 78.57%. Given Seer's higher possible upside, analysts clearly believe Seer is more favorable than Immunocore.

Valuation and Earnings

This table compares Immunocore and Seer's top-line revenue, earnings per share and valuation.

Profitability

This table compares Immunocore and Seer's net margins, return on equity and return on assets.

Immunocore (NASDAQ:IMCR) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and Nuvation Bio, as reported by MarketBeat.com.

Immunocore currently has a consensus price target of $54.3333, suggesting a potential upside of 34.79%. Nuvation Bio has a consensus price target of $17.40, suggesting a potential upside of 74.00%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Immunocore.

Valuation and Earnings

This table compares Immunocore and Nuvation Bio's top-line revenue, earnings per share and valuation.

Profitability

This table compares Immunocore and Nuvation Bio's net margins, return on equity and return on assets.

Summary

Nuvation Bio beats Immunocore on 3 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and ImmunityBio, as reported by MarketBeat.com.

Immunocore currently has a consensus price target of $54.3333, suggesting a potential upside of 34.79%. ImmunityBio has a consensus price target of $25.00, suggesting a potential upside of 49.34%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Immunocore.

Valuation and Earnings

This table compares Immunocore and ImmunityBio's top-line revenue, earnings per share and valuation.

Profitability

This table compares Immunocore and ImmunityBio's net margins, return on equity and return on assets.

Summary

ImmunityBio beats Immunocore on 2 of the 3 factors compared between the two stocks.